Health advertisers on Meta lose the detailed targeting options every other industry takes for granted, the same special ad category restrictions built for fair-housing compliance. LinkedIn adds its own review layer for HCP and investor audiences. The biotech and pharma companies that win on paid social aren't fighting these restrictions – they're building campaigns designed for the platform rules that actually apply to them.
The Problem
Special ad category rules strip out the targeting options your campaign plan assumed you'd have
Meta classifies most health-related advertising under its special ad category system, which removes age, gender, zip-code-level, and detailed interest targeting the same way it does for housing and employment ads. Teams that build a media plan around standard Meta targeting options discover mid-launch that half the plan isn't available, and end up either delaying launch or running a broader, less efficient campaign than the one they budgeted for.
Health claims get flagged by automated review with little explanation
Meta's ad review system flags health claims – efficacy language, before-and-after implications, condition-specific promises – through automated systems that don't always explain why an ad was rejected. Marketing teams burn cycles resubmitting slightly reworded creative without understanding what specifically triggered the flag, and repeated rejections put the whole ad account's standing at risk.
HCP-targeted campaigns on LinkedIn get built like general B2B campaigns and waste spend on the wrong audience
LinkedIn's professional targeting makes it the right platform for reaching physicians and clinical decision-makers, but campaigns built with generic B2B job-title targeting instead of validated HCP audience segments (specialty, NPI-adjacent firmographic data, institution type) burn budget on the wrong healthcare professionals or on non-clinical staff entirely. The platform's own pre-approval process for healthcare advertisers also catches teams off guard when they've already built creative around assumptions LinkedIn won't allow.
Investor and analyst-facing paid social gets deprioritized until there's a catalyst, then it's too late
Biotech companies often only think about paid social around a specific catalyst – a data readout, an FDA decision date, a conference presentation – and try to stand up targeted investor and analyst reach in the two weeks before the event. Platform review timelines and audience-building both take longer than that, so the campaign either launches too late to build pre-catalyst awareness or skips paid social entirely and relies on organic reach alone.
How We Help
Our initial assessment maps which of your planned campaigns fall under special ad category restrictions on Meta and which require LinkedIn's healthcare advertiser pre-approval, before any media plan gets built. This tells us what targeting is actually available for each audience – patient, HCP, investor – so the plan reflects platform reality instead of assumptions carried over from a non-health account.
Strategy development builds separate campaign logic for each audience because they need it. Unbranded, disease-awareness patient campaigns are designed around the reduced targeting set special ad category rules allow, using content and placement strategy to reach the right audience instead of granular demographic targeting. HCP campaigns on LinkedIn use validated professional audience data – specialty, institution type, seniority – built through LinkedIn's healthcare-compliant targeting options rather than generic firmographic filters. Investor and analyst-facing campaigns around a catalyst get planned on a calendar that accounts for platform review lead time, not the two weeks before the event.
Execution builds creative that clears platform health-claims review on the first pass more often, because we design copy and imagery against Meta and LinkedIn's actual policy language instead of writing consumer-style claims and hoping they pass. We manage the pre-approval process for LinkedIn healthcare advertising and the special ad category flow on Meta directly, so campaigns launch on schedule instead of stalling in review.
Measurement tracks audience-appropriate outcomes instead of one blended engagement metric. For unbranded patient campaigns, that's condition awareness and downstream site or HCP-locator traffic. For HCP campaigns, that's engagement from validated clinical audiences, not generic healthcare-industry job titles. For investor and analyst campaigns, that's reach and engagement within the specific pre-catalyst window when it actually matters for market perception.
What we deliver
- Platform compliance map – special ad category exposure on Meta and healthcare pre-approval requirements on LinkedIn, mapped per campaign audience
- Audience-specific campaign architecture – separate builds for unbranded patient, HCP, and investor/analyst audiences
- Health-claims-compliant creative – copy and imagery designed against actual Meta and LinkedIn policy language, not resubmitted guesses
- Catalyst calendar planning – investor and analyst campaign timing built around platform review lead time, not launched two weeks out
- Audience-appropriate reporting – condition awareness, validated HCP engagement, and pre-catalyst reach tracked separately, not blended
On Meta, a health advertiser loses the same targeting a housing advertiser loses – that's not a bug in your account setup, it's the special ad category system working as designed. The paid social programs that win stop fighting that restriction and build placement and creative strategy to do the targeting job instead.
Our Methodology
Our 90-day paid social build for biotech and pharma starts with a platform compliance audit, not a media plan. Phase one maps special ad category exposure on Meta and healthcare pre-approval requirements on LinkedIn for each audience you need to reach – patient, HCP, investor – and identifies what targeting and creative approach is actually available under those rules.
Phase two builds separate campaign architecture for each audience, since a patient-facing unbranded campaign, an HCP campaign, and an investor-facing campaign around a catalyst have almost nothing in common in terms of targeting, creative, or timing. We also build the catalyst calendar for investor and analyst campaigns far enough ahead that platform review doesn't eat into the pre-event awareness window.
Phase three launches with creative built against actual platform health-claims policy and manages the pre-approval and special ad category submission process directly, so campaigns go live on schedule. We track audience-specific outcomes from day one instead of retrofitting reporting after launch, because a blended engagement number tells you nothing useful when your three audiences behave completely differently.
How We Work
Initial paid social engagements for biotech and pharma companies run 3-4 months, with catalyst-driven investor campaigns sometimes requiring a longer lead-in depending on the event date. The first 30 days focus on platform compliance mapping and campaign architecture for each audience you're targeting.
Days 31-60 build and launch campaigns, including managing Meta's special ad category submission and LinkedIn's healthcare advertiser pre-approval process directly. Days 61-90 optimize based on real engagement data and expand creative testing within the compliant targeting boundaries.
Our team includes a paid social lead who owns platform compliance and account strategy, and a creative lead who builds claims-compliant ad content for each audience. From your side we need access to your regulatory or medical affairs team for content review on patient-facing claims, and advance notice of any investor catalyst dates so campaign timing accounts for platform review lead time.
Weekly reviews track campaign pacing and platform approval status. Monthly business reviews connect paid social activity to audience-specific outcomes – condition awareness for patient campaigns, validated HCP engagement, or pre-catalyst investor reach – rather than one combined metric.
- Faster campaign launches – fewer rejection cycles from creative built against actual platform health-claims policy
- Qualified HCP engagement – reach concentrated on validated clinical audiences instead of generic healthcare job titles
- Condition awareness lift – unbranded patient campaigns performing within special ad category targeting limits
- On-time catalyst coverage – investor and analyst campaigns live ahead of the event, not launched too late to matter
If your biotech & pharma company needs paid social leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a paid social engagement cost for a biotech or pharma company?
Most engagements run as a monthly management fee of $8K-$22K, separate from ad spend, scoped to how many distinct audiences you're targeting. A program covering only unbranded patient awareness costs less than one also running HCP campaigns on LinkedIn and investor-facing campaigns around a catalyst, since each requires separate platform compliance work and creative. We scope the fee after mapping which audiences and platforms are actually in play.
Why can't we use the same detailed targeting on Meta that other industries get?
Meta classifies most health advertising under its special ad category system, the same framework used for housing and employment ads, which removes age, gender, granular location, and detailed interest targeting to prevent discriminatory ad delivery. This applies broadly across health advertisers, not just to your account specifically. We design placement, content, and audience strategy to reach the right people within those limits instead of planning around targeting options that were never going to be available.
How does HCP targeting work on LinkedIn if we can't use standard job-title filters?
We use validated professional audience data – specialty, institution type, and clinical seniority signals – rather than generic B2B job-title targeting that catches non-clinical staff along with the physicians you actually want to reach. LinkedIn also requires healthcare advertisers to go through a pre-approval process before certain campaign types launch, which we manage directly so the campaign isn't held up mid-flight. The goal is spend concentrated on people who actually influence clinical decisions.
How far ahead do we need to plan a paid social campaign around an investor catalyst?
We recommend starting campaign planning at least 6-8 weeks before a known catalyst date – a data readout, an FDA decision, a major conference – because platform review timelines and audience-building both take real time, and a campaign launched two weeks out rarely has time to build meaningful pre-event reach. If your catalyst timeline is already inside that window, we can still launch, but the awareness-building runway is shorter and expectations need to reflect that.
What makes Winston Francois different from a general paid social agency for pharma accounts?
Most general paid social agencies learn special ad category restrictions and LinkedIn's healthcare pre-approval process the hard way, through a stalled or rejected campaign. We map platform compliance before building the media plan, which is what keeps launches on schedule. We're operators who build separate campaign logic for patient, HCP, and investor audiences instead of running one blended strategy that underperforms for all three.
What type of biotech or pharma company is the right fit for this service?
Commercial-stage companies running unbranded disease-awareness campaigns, companies building HCP engagement programs on LinkedIn, and pre-commercial or clinical-stage biotech companies with investor and analyst audiences to reach around upcoming catalysts. If your team has had ads rejected repeatedly on Meta or gotten stuck in LinkedIn's healthcare review process, that's usually the clearest signal the current approach needs rebuilding. The first step is a platform compliance audit of your current or planned campaigns.
